New schizophrenia pill aims to keep symptoms at bay
NCT ID NCT07227818
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether the experimental drug NBI-1117568 can delay relapse of schizophrenia symptoms compared to a placebo. About 560 adults with stable schizophrenia will first receive the drug openly, then be randomly assigned to continue it or switch to placebo. The main goal is to see how long it takes for symptoms to return.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-1117568 (oral capsules)
What this could lead to
If successful, this could provide a new treatment option to help people with schizophrenia maintain stability and prevent symptom relapse.
What could go wrong
This is an early Phase 3 study, so results are not yet proven. The drug may not work better than placebo, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGGarden Grove, California, 92845, United States
-
Neurocrine Clinical Site
RECRUITINGLa Habra, California, 90631, United States
-
Neurocrine Clinical Site
RECRUITINGLemon Grove, California, 91945, United States
-
Neurocrine Clinical Site
RECRUITINGOceanside, California, 92056, United States
-
Neurocrine Clinical Site
RECRUITINGTorrance, California, 90504, United States
-
Neurocrine Clinical Site
RECRUITINGWest Hills, California, 91307, United States
-
Neurocrine Clinical Site
RECRUITINGHollywood, Florida, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGMaitland, Florida, 32751, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33122, United States
-
Neurocrine Clinical Site
RECRUITINGMiami, Florida, 33155, United States
-
Neurocrine Clinical Site
RECRUITINGTampa, Florida, 33629, United States
-
Neurocrine Clinical Site
RECRUITINGWest Palm Beach, Florida, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30318, United States
-
Neurocrine Clinical Site
RECRUITINGBoston, Massachusetts, 02116, United States
-
Neurocrine Clinical Site
RECRUITINGFlowood, Mississippi, 39232, United States
-
Neurocrine Clinical Site
RECRUITINGCedarhurst, New York, 11516, United States
-
Neurocrine Clinical Site
RECRUITINGNew York, New York, 10029, United States
-
Neurocrine Clinical Site
RECRUITINGNew York, New York, 10036, United States
-
Neurocrine Clinical Site
RECRUITINGThe Bronx, New York, 10461, United States
-
Neurocrine Clinical Site
RECRUITINGBellevue, Washington, 98007, United States